<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="71093"><DrugName>LY-2928057</DrugName><DrugSynonyms><Name><Value>LY-2928057</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>ferroportin mAb (anemia), Eli Lilly</Value></Name></DrugSynonyms><CompanyOriginator id="17810">Eli Lilly &amp; Co</CompanyOriginator><CompaniesSecondary><Company id="17810">Eli Lilly &amp; Co</Company></CompaniesSecondary><CrossReferences><SourceEntity id="71093" type="Drug"><TargetEntity id="732472" type="siDrug">LY-2928057</TargetEntity></SourceEntity><SourceEntity id="17810" type="Company"><TargetEntity id="4295904414" type="organizationId">Eli Lilly and Co</TargetEntity></SourceEntity><SourceEntity id="17" type="ciIndication"><TargetEntity id="10002034" type="MEDDRA"></TargetEntity><TargetEntity id="D000740" type="MeSH"></TargetEntity><TargetEntity id="-201701473" type="omicsDisease"></TargetEntity><TargetEntity id="988" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="63269" type="Action"><TargetEntity id="6330" type="Mechanism">Anti-SLC40A1 (Solute Carrier Family 40 Member 1)</TargetEntity><TargetEntity id="7112" type="Mechanism">Solute Carrier Family 40 Member 1 (SLC40A1)  Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-11189" type="ciTarget"><TargetEntity id="1016336300613" type="siTarget">Solute carrier family 40 member 1</TargetEntity><TargetEntity id="-1662611254" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="17">Anemia</Indication></IndicationsSecondary><ActionsPrimary><Action id="63269">Solute carrier family 40A1 inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="1546">Blood system agent</Action></ActionsSecondary><Technologies><Technology id="648">Intravenous formulation</Technology><Technology id="740">Infusion</Technology><Technology id="169">Monoclonal antibody humanized</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="573">Immunoglobulin-G</Technology></Technologies><LastModificationDate>2017-09-19T09:05:17.000Z</LastModificationDate><ChangeDateLast>2016-04-29T00:00:00.000Z</ChangeDateLast><AddedDate>2011-04-20T15:00:15.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="17810" linkType="Company"&gt;Eli Lilly&lt;/ulink&gt; was developing LY-2928057,  a  humanized IgG4 mAb that binds to human ferroportin and blocks it binding  to hepcidin, for the potential iv infusion treatment of anemia   [&lt;ulink linkID="1185359" linkType="Reference"&gt;1185359&lt;/ulink&gt;]. In April 2014, Lilly began listing the mAb as in phase II for anemia [&lt;ulink linkID="1550480" linkType="Reference"&gt;1550480&lt;/ulink&gt;]; this was still the case in January 2016 [&lt;ulink linkID="1730416" linkType="Reference"&gt;1730416&lt;/ulink&gt;]. However, by April 2016, development of the mAb had been discontinued [&lt;ulink linkID="1756099" linkType="Reference"&gt;1756099&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In December 2013, a multiple-dose, dose-escalation, randomized, placebo-controlled, phase I study (&lt;ulink linkID="161682" linkType="Protocol"&gt;NCT01991483&lt;/ulink&gt;; 15268; I5M-MC-FABC) was initiated in the US in hemodialysis patients (expected n = 54). The trial was completed in October 2015; only 20 subjects had been enrolled [&lt;ulink linkID="1550498" linkType="Reference"&gt;1550498&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2011, a randomized, single-blind, placebo-controlled, dose-escalation, phase I trial (&lt;ulink linkID="76461" linkType="Protocol"&gt;NCT01330953&lt;/ulink&gt;; 14151, I5M-FW-FABA) to evaluate the safety and pharmacokinetics of LY-2928057 began in healthy subjects (n = 48) in Singapore. The trial was completed in September 2011 [&lt;ulink linkID="1185359" linkType="Reference"&gt;1185359&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In December 2013, preclinical data were presented at the 55th ASH Meeting in New Orleans, LA. Increase in ferritin levels induced by hepcidin was significantly and dose-dependently inhibited by LY-2928057 in Caco-2 cells. Single bolus dose of LY-2928057 (0, 0.3, 1, 3, 10 and 30 mg/kg iv) dose-dependently increased serum iron levels in normal cynomolgus monkeys; however no differences were observed at 10 and 30 mg/kg dose levels [&lt;ulink linkID="1503293" linkType="Reference"&gt;1503293&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="17">Anemia</Indication><StatusDate>2016-04-19T00:00:00.000Z</StatusDate><Source id="1756099" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="5">Other</DiscontinuedReason><Indication id="17">Anemia</Indication><StatusDate>2016-04-19T00:00:00.000Z</StatusDate><Source id="1756099" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="17">Anemia</Indication><StatusDate>2013-12-31T00:00:00.000Z</StatusDate><Source id="1550498" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="17">Anemia</Indication><StatusDate>2011-03-15T00:00:00.000Z</StatusDate><Source id="1185359" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17810">Eli Lilly &amp; Co</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="17">Anemia</Indication><StatusDate>2014-04-21T00:00:00.000Z</StatusDate><Source id="1550480" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-11189"><Name>Solute carrier family 40A1</Name><SwissprotNumbers><Swissprot>Q923U9</Swissprot><Swissprot>Q9I9R3</Swissprot><Swissprot>Q9JHI9</Swissprot><Swissprot>Q9NP59</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><PatentFamilies><PatentFamily id="2355179" number="WO-2010065496" title="Anti-ferroportin 1 monoclonal antibodies and uses thereof"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Eli Lilly &amp; Co" id="17810"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>